## Author Relationships With Industry and Other Entities (COMPREHENSIVE)—2019 AATS/ACC/SCAI/STS Expert Consensus Systems of Care Document: Operator and Institutional Recommendations and Requirements for Transcatheter Mitral Valve Repair (February 12, 2019)

Committee Member	Employment	Consultant	Speakers Bureau	Ownership/ Partnership/ Principal	Personal Research	Institutional, Organizational, or Other Financial Benefit	Expert Witness
Robert O. Bonow, (Chair)	Northwestern University— Feinberg School of Medicine	None	None	None	None	• JAMA* • NHLBI†	None
Patrick T. O'Gara, (Vice-Chair)	Harvard Medical School— Professor of Medicine; Brigham and Women's Hospital Cardiovascular Division—Director, Clinical Cardiology	None	None	None	None	<ul> <li>Edwards Lifesciences†</li> <li>JAMA Cardiology*</li> <li>Medtronic</li> <li>Medtrace†</li> <li>NIH*</li> </ul>	None
David H. Adams	Mount Sinai Health System—Cardiac Surgeon- in-Chief; Icahn School of Medicine at Mount Sinai and The Mount Sinai Hospital— Marie-Josee and Henry R. Kravis Professor and Chairman Department of Cardiovascular Surgery	None	None	None	Medtronic     NeoChord	• Edwards Lifesciences* • Medtronic*	None
Vinay Badhwar	West Virginia University— Gordon F. Murray Professor; Chair, Department of Cardiovascular and Thoracic Surgery; Executive Chair, WVU Heart & Vascular Institute	None	None	None	None	• Tendyne, Inc.‡ • Abbott Laboratories‡	None
Joseph E. Bavaria	Hospital of the University of Pennsylvania—Director, Thoracic Aortic Surgery Program	• St. Jude Medical/Abbott • W.L. Gore*	None	None	Cytosorbents† Edwards Lifesciences† Medtronic Cardiovascular† St. Jude Medical/Abbott† Terumo Aortic† W.L. Gore†	Medtronic†‡     Edwards     Lifesciences†‡	None
Sammy Elmariah	Massachusetts General	AstraZeneca	None	None	• Edwards	• Abbott‡	None

Committee Member	Employment	Consultant	Speakers Bureau	Ownership/ Partnership/ Principal	Personal Research	Institutional, Organizational, or Other Financial Benefit	Expert Witness
	Hospital—Director, Interventional Cardiology Research, Division of Cardiology	Medtronic			Lifesciences*	Medtronic‡     St. Jude‡	
Judy W. Hung	Massachusetts General Hospital—Associate Director, Echocardiography, Division of Cardiology	None	None	None	• CTSN • NIH/NHLBI CTSN†	• Edwards Lifesciences§	None
JoAnn Lindenfeld	Vanderbilt University Medical Center—Director, Advanced Heart Failure Professor of Medicine	<ul> <li>Abbott Laboratories</li> <li>Boston Scientific</li> <li>CVRx</li> <li>Edwards Lifesciences</li> <li>Relypsa*</li> <li>ResMed*</li> <li>VWAVE*</li> </ul>	None	None	• AstraZeneca† • Novartis*	AstraZeneca‡	None
Alanna Morris	Emory University Clinical Cardiovascular Research Institute—Assistant Professor of Medicine, Division of Cardiology	None	None	None	None	None	None
Ruby Satpathy	Baptist Medical Center— Medical Director, Structural Heart Program; Associate Director, Cardiac Catheterization Laboratory	None	None	None	None	• Abbott Laboratories‡ • Boston Scientific‡	None
Brian Whisenant	Intermountain Heart Institute Cardiology—Medical Director, Heart Valve and Structural Heart Disease	Boston Scientific*     Edwards Medical*     Johnson & Johnson*	None	BioTrace     Medical*	• Edwards Lifesciences†	<ul><li>Abbott     Laboratories‡</li><li>Edwards‡</li><li>Medtronic‡</li></ul>	None
Y. Joseph Woo	Stanford University School of Medicine—Norman E. Shumway Professor; Chair, Department of Cardiothoracic Surgery	None	None	None	None	• NIH*	None

This table represents all relationships of committee members with industry and other entities that were reported by authors, including those not deemed to be relevant to this document, at the time this document was under development. The table does not necessarily reflect relationships with industry at the time of publication. A person is deemed to have a significant interest in a business if the interest represents ownership of  $\geq 5\%$  of the voting stock or share of the business entity, or ownership of  $\geq \$5,000$  of the fair market value of the business entity; or if funds received by the person from the business entity exceed 5% of the person's gross income for the previous year. Relationships that exist with no financial benefit are also included for the

purpose of transparency. Relationships in this table are modest unless otherwise noted. Please refer to <a href="http://www.acc.org/guidelines/about-guidelines-and-clinicaldocuments/relationships-with-industry-policy">http://www.acc.org/guidelines/about-guidelines-and-clinicaldocuments/relationships-with-industry-policy</a> for definitions of disclosure categories or additional information about the ACC/AHA Disclosure Policy for Writing Committees.

- \* Significant relationship.
- † No financial benefit.
- ‡ Relationship with this company is limited to enrolling patients in clinical trials. This disclosure was entered under the Clinical Trial Enroller category in the ACC's disclosure system. To appear in this category, the author acknowledges that there is no direct or institutional relationship with the trial sponsor as defined in the ACC/AHA Disclosure Policy for Writing Committees.
- \$Dr. Hung is director of the Massachusetts General Hospital Echo Core Laboratory, which is funded by Edwards Lifesciences through Edwards' acquisition of Harpoon Medical. Dr. Hung's relationship with Edwards/Harpoon was disclosed after the initial publication of this document

CTSN=Cardiothoracic Surgical Trials Network; JAMA=Journal of the American Medical Association; NHLBI= National Heart, Lung, and Blood Institute; NIH=National Institutes of Health.